| Similar Articles |
|---|
 |
The Motley Fool
July 26, 2006
Brian Lawler |
Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note.   |
The Motley Fool
March 15, 2007
Brian Lawler |
Dueling Fools: Elan Bear Rebuttal With so many risks and unknowns embedded in Tysabri, investors should not be convinced Elan can provide a miracle. |
The Motley Fool
February 8, 2005
Charly Travers |
Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance. |
Pharmaceutical Executive
November 1, 2008
Jim Wahl |
The Mess in MS A five-year forecast of the multiple-sclerosis market following the disruptions of Tysabri. |
Chemistry World
February 8, 2013
Andrew Turley |
Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis. |
The Motley Fool
April 22, 2011
MedCity News |
Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments. |
The Motley Fool
October 18, 2007
Brian Lawler |
Genzyme Shows Off a Drug Candidate A top compound in development could become an important MS treatment. |
Chemistry World
December 4, 2013
Phillip Broadwith |
Celgene buys into anticancer antibodies US firms Celgene and OncoMed have tied up a deal to develop and commercialize biological therapies for cancer. |
The Motley Fool
January 29, 2010
Brian Orelli |
Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead. |
BusinessWeek
March 14, 2005
Arnst & Barrett |
Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments |
The Motley Fool
January 2, 2012
Anders Bylund |
What Will Elan Do for an Encore? 2011 was a great year for the Irish biotech. Here's how that momentum carries through into 2012. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
Chemistry World
October 23, 2015
Philippa Matthews |
Biogen to cut 800 jobs worldwide The company will cut over 800 jobs in an effort to reduce annual operating costs by approximately $250 million. |
Science News
February 19, 2005 |
Multiple Sclerosis In addition to explaining the autoimmune disorder in detail, this Web site offers links to sites that delve into treatments, current research, fundraising events, clinical trials of new drugs, and breaking news stories about MS. |
The Motley Fool
May 26, 2004
Charly Travers |
Elan and Biogen File for Approval There's a new multiple sclerosis drug on the horizon. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
February 28, 2005
Charly Travers |
Another Drug Sector Shocker Patient death triggers voluntary withdrawal of MS drug Tysabri. Both BiogenIDEC and Elan have been rocked in trading today, down 41% and 68%, respectively, so far. |
The Motley Fool
June 18, 2007
Billy Fisher |
Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high. |
The Motley Fool
December 13, 2004
Charly Travers |
PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success. |
The Motley Fool
March 15, 2007
Anders Bylund |
Dueling Fools: Elan Bull Granted, Elan isn't a stock for impatient investors, but those with patience will be rewarded in spades. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
The Motley Fool
October 31, 2006
Brian Lawler |
A Foolish Trick: Elan Debt is coming due, and there's too much reliance on a single drug. Investors, beware. |
The Motley Fool
February 18, 2004
Jeff Hwang |
Elan's Early Submission Elan and Biogen Idec will submit a multiple sclerosis treatment ahead of schedule. |
The Motley Fool
December 7, 2004
Charly Travers |
Spin the Medicine Bottle Is a new MS drug going to be a top seller or a bottom-dweller? Here's how to find out. Before investing in any pharmaceutical company with a product in development, go through this exercise to estimate the new drug's potential. |
The Motley Fool
June 8, 2010
Ryan McBride |
Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks. |
The Motley Fool
July 24, 2009
Brian Orelli |
Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday? |
Chemistry World
July 8, 2015
Phillip Broadwith |
Celgene backs immunotherapy with Juno collaboration US biopharmaceutical firm Celgene is to bolster its position in the emerging field of cell therapy through a collaboration with biotech Juno Therapeutics. |
The Motley Fool
November 24, 2004
Charly Travers |
A Blockbuster Drug Gains Approval Biogen IDEC and Elan announced that Tysabri had been approved by the FDA for the treatment of muliple sclerosis (MS). Tysabri has long been regarded as a drug that will generate a whopping level of sales. |
The Motley Fool
March 16, 2007
Brian Lawler |
PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note. |
The Motley Fool
October 6, 2010
Brian Orelli |
Celgene Is All Grown Up An acquirer is on the prowl. |
The Motley Fool
October 31, 2011
Brian Orelli |
When You've Got It, You've Got It Biogen keeps its good-news streak going. |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Multiple Sclerosis: The Advent of the Orals The $8 billion dollar multiple sclerosis market is set to double the number of available treatments in the near future, with a dramatic switch from injectables to oral medications. |
The Motley Fool
October 28, 2011
Brian Orelli |
Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever. |
The Motley Fool
May 2, 2007
Brian Lawler |
Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note. |
The Motley Fool
March 15, 2007
Brian Lawler |
Dueling Fools: Elan Bear How do you bring an Elan bear out of hibernation? Combine a crushing debt load, a huge cloud of uncertainty over its lead developmental drug program, and the launch of a new product that won't bring in enough revenue to sustain the current valuation, et voila! A bear is born. |
The Motley Fool
March 1, 2006
Bill Mann |
Tysabri: As Bad as AIDS? A report on the Elan/Biogen drug gets blown out of proportion on the eve of an FDA review. To say that a lot rides on the outcome of this meeting for Elan shareholders is an understatement. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
Chemistry World
August 14, 2012
Andrew Turley |
Elan spins off drug discovery Irish drug maker Elan is to spin off its drug discovery activities as an independent company of 80 employees -- just under half the Elan workforce -- called Neotope Biosciences. The new company will focus on chronic degenerative diseases. |
The Motley Fool
June 2, 2008
Brian Orelli |
Valuing One-Drug Wonders With only one drug on the market, these pharmas lack positive earnings. |
The Motley Fool
September 15, 2009
Brian Orelli |
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
November 20, 2007
Brian Orelli |
Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future. |
The Motley Fool
August 1, 2008
Brian Lawler |
Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug. |
The Motley Fool
April 25, 2008
Brian Lawler |
Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook. |
The Motley Fool
April 5, 2005
Charly Travers |
Has Elan Been KO'd? Tysabri is derailed but not necessarily off-track forever. The FDA needs to consider whether the real benefits to these patients outweigh the risk. But that's a highly uncertain outcome and a heck of decision on which to bet some investment dollars. |
The Motley Fool
August 29, 2006
Brian Lawler |
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. |
The Motley Fool
March 8, 2005
Charly Travers |
After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market. |
The Motley Fool
March 26, 2009
Brian Orelli |
R&D Your Way to Higher Sales Biogen is trying to lower side effects to increase sales. |
